Skip to main content
. 2015 Sep 7;6(32):33269–33278. doi: 10.18632/oncotarget.5037

Figure 5. miR-130a and miR-495 increases cell proliferation and tumor angiogenesis.

Figure 5

A. SNU484 cells were transfected with miR-130a and miR-495 mimics (10 nM). Apoptotic cells were monitored by annexin V-FITC/PI staining and flow-cytometry analysis. The right-lower quadrant shows early apoptotic cells, while the right-upper quadrant shows late apoptotic cells. B. SNU484 cells were transfected with miR-130a and miR-495 mimics (10 nM). Expression of p21 and Bim was assessed by western blot. C. BrdU incorporation assays were performed 24 and 48 h after the transfection of SNU484 cells with miR-130a and miR-495 mimics (20 nM) (n ≥ 3, triplicate). *p < 0.01 vs. control. D. The cell growth capacity of SNU484 cells transfected with miR-130a and miR-495 mimics (20 nM) was detected by colony formation assays (n ≥ 3, triplicate). *p < 0.05. **p < 0.01 vs. control. E. Conditioned medium of SNU484 cells transfected with miR-130a and miR-495 inhibitors (50 nM) were collected and levels of secreted VEGF were determined by ELISA. F. Matrigel was presoaked in conditioned medium of SNU484 cells transfected with miR-130a and miR-495 inhibitors (50 nM) and injected subcutaneously into C57BL/6 mice. After 7 days, the matrigel plugs were removed and photographed (n ≥ 5, triplicate). *p < 0.05. **p < 0.01 vs. control.